A 67-year-old man in the UK has become the first participant in a trial for a new lung cancer vaccine, BNT116, developed by BioNTech. The vaccine, which uses mRNA technology similar to COVID-19 vaccines, aims to instruct the immune system to target and destroy lung cancer cells, potentially reducing side effects by focusing on cancer cells rather than healthy ones. The trial, involving 130 patients across seven countries, will assess the safety and efficacy of the vaccine when used alongside standard treatments like immunotherapy and chemotherapy.
https://www.bbc.com/news/articles/ce806ndv8neo
A groundbreaking lung cancer vaccine has entered clinical trials across seven countries. This vaccine, designed to target and prevent the recurrence of lung cancer, represents a significant advancement in oncology. If successful, it could offer a new preventative strategy against one of the deadliest forms of cancer.
Ils en parlent : https://www.journaldequebec.com/2024/08/23/revolutionnaire-un-premier-vaccin-contre-le-cancer-des-poumons-a-lessai-dans-sept-pays
0 Comments